Tag:
elesclomol
Latest Headlines
Latest Headlines
Synta halts "stunningly disappointing" melanoma trial
In a devastating blow to the company, Synta Pharmaceuticals has halted a Phase III melanoma drug trial after a greater number of people taking elesclomol died than those receiving standard care. The
Synta's billion-dollar drug nears end of Phase III
Synta Pharmaceuticals has reached a key point in its development of the cancer therapy elesclomol . The developer is set to announce today that it has completed enrollment in a confirmatory Phase III
Synta gets $15M milestone from GSK
Synta Pharmaceuticals has garnered a $15 million payment from GlaxoSmithKline as part of its collaboration agreement for the cancer drug elesclomol. Elesclomol is in Phase III trials for metastatic
